Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04287621 · ClinicalTrials.gov registry record
Registry of Asthma Patients Initiating DUPIXENT®
A clinical trial of Asthma, sponsored by Regeneron Pharmaceuticals.
- Active
- Registry status
- 718
- Enrollment target
- 20
- Study locations
NCT04287621: Active study of Asthma, sponsored by Regeneron Pharmaceuticals.
NCT04287621 is a study of Asthma that is active but no longer recruiting, run by Regeneron Pharmaceuticals. The registered enrollment target is 718 participants, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04287621, a study of Asthma, is active but no longer recruiting, sponsored by Regeneron Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 718 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life. This includes characterization of: * Patient demographics (eg, gender, age, and race) * Patient baseline characteristics (eg, prior medications and procedures, medical history, asthma history, weight, height) The secondary objectives of the study are: * To characterize real-world use patterns of DUPIXENT® for asthma * To assess the long-term effectiveness of DUPIXENT® in asthma patients in a real-world setting * To assess effectiveness on comorbid type 2 inflammatory conditions in asthma patients treated with DUPIXENT® * To collect long-term safety data on study participants in the real-world setting
Primary Outcome
Including gender, age, race
Conditions Studied
Interventions
- DRUG DUPIXENT®
Study Locations (20)
Florida
- Global Research Solutions - Hollywood
- Memorial Healthcare System - Hollywood
- Clinical Research Specialists, LLC - Kissimmee
- Kratz Allergy & Asthma - Port Richey
- GCP, Global Clinical Professionals - St. Petersburg
- Allergy & Asthma Diagnostic Treatment Center - Tallahassee
California
- Children's Hospital of Orange County - Orange
- Riviera Allergy Medical Center - Redondo Beach
- Allergy & Asthma Medical Group and Research, A PC - San Diego
- Bensch Clinical Research, LLC - Stockton
- Allianz Research Institute, Inc. - Westminster
Georgia
- Omni Allergy - Atlanta
- Columbus Regional Research Institute - Columbus
- IACT Health Southeast Lung Associates - Rincon
Arizona
- Arizona Allergy & Immunology Research - Gilbert
- Medical Research of Arizona, a Division of Allergy, Asthma & Immunology Associates, Ltd. - Scottsdale
Illinois
- Northwestern Medical Group Allergy & Immunology Clinic - Chicago
- The University of Chicago - Chicago
Alabama
- Clinical Research Center of Alabama, LLC - Birmingham
Idaho
- Treasure Valley Medical Research - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 718 participants |
| Start Date | 2020-03-02 |
| Est. Completion | 2026-04-27 |
What the registry record for NCT04287621 still lists
NCT04287621 is an observational study that tracks outcomes without assigning an intervention. The registered 718 participants enrollment target is mid-sized for trials with a published cap, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which DUPIXENT® is the first listed.
NCT04287621 names 20 study sites across 7 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT04287621 about?
NCT04287621 is a clinical study titled "Registry of Asthma Patients Initiating DUPIXENT®". The primary objective of the study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life. This includes characterization of: * Patient demographics (eg, gender, age, and race) * Patient...
What is the current status of trial NCT04287621?
This trial is currently active not recruiting. The enrollment target is 718 participants. The study started on 2020-03-02. Estimated completion is 2026-04-27.
What conditions does trial NCT04287621 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT04287621?
The interventions under investigation include: DUPIXENT® (DRUG).
Who is sponsoring clinical trial NCT04287621?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04287621 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04287621's enrollment target sits among peer trials
718 59th of 374 higher than 316 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Innate Immunity in Allergic Asthma
RECRUITING
-
Automated Inhaler Monitoring for Asthma Medication Usage
RECRUITING · NA
-
Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology
RECRUITING
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04916327 · 720 participants · NA
Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1
- NCT05047224 · 720 participants · NA
Addressing Disparities in Autism Spectrum Disorder Diagnosis Using a Direct-to-home Telemedicine Tool
- NCT05309395 · 720 participants · Phase 3
Food Prescriptions to Promote Affordable Diets
- NCT05466214 · 720 participants · NA
Systematic Efficacy Replication Study of Conjoint Behavioral Consultation in Elementary Schools
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI